Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VECTIBIX plus oxaliplatin-based adjuvant treatment of rectal cancer
2009-013756-79Phase 2Terminated
- Sponsor
- Anticancer Informing "Me Gnosi Nika"
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in rectal cancer and colorectal cancer (CRC), sponsored by Anticancer Informing "Me Gnosi Nika". Primary endpoints: Incidence of unacceptable toxicity and Incidence of all grades panitumumab-related toxicity. Started Oct 2010; status: terminated.
02
Drugs
panitumumab
03
Conditions
rectal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2009-013756-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013756-79.